Cemiplimab for Unresectable Cutaneous Squamous Cell Carcinoma: Experience From a Tertiary Center
Cutis · 01.05.2026 · 5 (117)
DOI: 10.12788/cutis.1410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cutis, erschienen am 01.05.2026. Verfasst von Arka Banerjee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Arka Banerjee is from St. George's Hospital, London, United Kingdom, and City St. George's, University of London, United Kingdom. Dr. Murphy is from …. Hauptthemen laut MEDLINE: Cutaneous Squamous Cell Carcinoma, Skin Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Arka Banerjee is from St. George's Hospital, London, United Kingdom, and City St. George's, University of London, United Kingdom. Dr. Murphy is from St. Andrew's Centre for Plastic Surgery and Burns, Broomfield Hospital…
Zitieren
APA
Banerjee, A., Murphy, S., Gatfield, E., Ince, W., Fife, K., & Durrani, A. (2026). Cemiplimab for Unresectable Cutaneous Squamous Cell Carcinoma: Experience From a Tertiary Center. Cutis, 5(117). https://doi.org/10.12788/cutis.1410
Vancouver
Banerjee A, Murphy S, Gatfield E, Ince W, Fife K, Durrani A. Cemiplimab for Unresectable Cutaneous Squamous Cell Carcinoma: Experience From a Tertiary Center. Cutis. 2026;5(117). doi:10.12788/cutis.1410
BibTeX
@article{Banerjee2026,
author = {Banerjee, Arka and Murphy, Suzanne and Gatfield, Elinor and Ince, Will and Fife, Kate and Durrani, Amer},
title = {Cemiplimab for Unresectable Cutaneous Squamous Cell Carcinoma: Experience From a Tertiary Center},
journal = {Cutis},
year = {2026},
volume = {5},
number = {117},
doi = {10.12788/cutis.1410}
}
EUVIMED